Cochrane for Clinicians
Putting Evidence into Practice

Smectite for Acute Infectious Diarrhea in Children

Dustin K. Smith, DO, Naval Branch Health Clinic Diego Garcia, Naval Hospital Yokosuka, Yokosuka, Japan
Nadine S. Barksdale, MD, and Joshua D. Sohn, MD, Naval Hospital Jacksonville, Jacksonville, Florida

Author disclosure: No relevant financial affiliations.

Clinical Question
Is smectite safe and effective for the treatment of acute infectious diarrhea in children?

Evidence-Based Answer
When compared with placebo, smectite decreases the duration of diarrhea by about a day, with a mean difference (MD) of 24.4 fewer hours of diarrhea (95% confidence interval [CI], 17.9 to 30.9 hours). Smectite also decreases stool output by 11.4 g per kg (95% CI, 0.8 to 22 g per kg). Children using smectite are more likely to have resolution of diarrhea by day 3 (number needed to treat = 2.7). There is no difference in the number of children requiring intravenous rehydration therapy or hospitalization. No serious adverse effects or deaths have been reported in children using smectite. (Strength of Recommendation: C, based on consensus, disease-oriented evidence, usual practice, expert opinion, or case series.)

Practice Pointers
Acute diarrhea is the passage of three or more loose stools per day. In the United States, diarrhea accounts for 1% of deaths in patients younger than five years. Diarrhea is commonly caused by infection from contaminated food and water, or transmitted via fecal-oral route. Smectite is a natural, medicinal clay formed from sheets of aluminum and magnesium silicate. It is an oral adjuvant for diarrhea that is used outside of—and not commonly available in—the United States. It typically comes as a powder that is dissolved in water and is available without a prescription. Smectite is proposed to reduce gut inflammation, reduce toxin penetration by acting as a barrier, and increase water absorption.

This Cochrane review included 18 trials with 2,616 children. Studies were conducted in high-income and low- to middle-income countries (the United States was not represented) and included hospital and ambulatory settings. Most studies involved infants and children one to 24 months of age, although nine studies also included children up to 12 years of age. Both breastfed and nonbreastfed children were represented. Rotavirus was the most commonly reported etiology of diarrhea. Smectite administration varied from 1 to 6 g per dose, at intervals of one to four times per day, with varying durations (i.e., from three to six days or until recovery).

The primary outcome for the Cochrane review was duration of diarrhea. Fifteen studies (2,209 participants) reported duration with varying definitions for resolution (i.e., time to last loose stool, time to first formed stool, time to first soft or formed stool, and time to normalization of stool). The mean duration of diarrhea in the smectite group was 24.4 fewer hours than in the control group (95% CI, 17.9 to 30.9). More participants in the smectite group achieved resolution of diarrhea by day 3 (number needed to treat = 2.7; 95% CI, 1.5 to 9.8).

The secondary outcomes evaluated were stool frequency, volume of stool output, the need for hospitalization, and the need for intravenous access for rehydration. Children stools less frequently when treated with smectite (MD = 1.3 fewer episodes per day; 95% CI, 0.4 to 2.3 fewer episodes) and, when they did, had decreased stool output (MD = 11.4 g per kg; 95% CI, 0.8 to 21.9 g per kg). There was no difference in the need for hospitalization or the need for intravenous access for rehydration.
No serious adverse effects or deaths were reported in any of the studies. Constipation was the most commonly reported adverse effect of smectite, although there were few events.

Current National Institute for Health and Care Excellence guidelines focus on preventing and managing dehydration for children with diarrhea and vomiting and specifically recommend against using antidiarrheal medications. Smectite could be of benefit in countries with limited availability of oral or intravenous rehydration therapy, especially in patients with preexisting malnutrition.

The practice recommendations in this activity are available at http://www.cochrane.org/CD011526.

**Editor’s Note:** The numbers needed to treat and confidence intervals reported in this Cochrane for Clinicians were calculated by the authors based on raw data provided in the original Cochrane review.

**The views** expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Uniformed Services University of the Health Sciences, Department of Defense, or the U.S. government.

**We are** military service members. This work was prepared as part of our official duties. Title 17 U.S.C. 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines United States Government work as a work prepared by a military service member or employee of the United States Government as part of that person’s official duties.

**References**


---

**SUMMARY TABLE: SMECTITE VS. CONTROL FOR ACUTE INFECTIOUS DIARRHEA IN CHILDREN**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects</th>
<th>Number of participants (number of studies)</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of diarrhea</td>
<td>Risk with control: Mean of 32.6 to 118.9 hours</td>
<td>Risk with smectite (95% CI): MD = 24.4 fewer hours (17.9 to 30.9)</td>
<td>2,209 (15 RCTs)</td>
</tr>
<tr>
<td></td>
<td>342 per 1,000</td>
<td>718 per 1,000 (445 to 1,000; NNT = 2.7 [1.5 to 9.8])</td>
<td>312 (5 RCTs)</td>
</tr>
<tr>
<td>Clinical resolution at day 3</td>
<td>Mean of 1.9 to 3.2 episodes per day</td>
<td>MD = 1.3 fewer episodes per day (0.4 to 2.3)</td>
<td>954 (3 RCTs)</td>
</tr>
<tr>
<td>Stool frequency</td>
<td>Mean of 90.7 to 118.8 g per kg</td>
<td>MD = 11.37 g per kg decrease (21.94 to 0.79 g per kg)</td>
<td>634 (3 RCTs)</td>
</tr>
<tr>
<td>Need for hospitalization</td>
<td>85 per 1,000</td>
<td>79 per 1,000 (64 to 98)</td>
<td>885 (2 RCTs)</td>
</tr>
<tr>
<td>Need for intravenous access for rehydration</td>
<td>676 per 1,000</td>
<td>520 per 1,000 (365 to 750)</td>
<td>81 (1 RCT)</td>
</tr>
<tr>
<td>Adverse effects: constipation</td>
<td>0 per 1,000</td>
<td>61 per 1,000</td>
<td>128 (2 RCTs)</td>
</tr>
</tbody>
</table>

CI = confidence interval; MD = mean difference; NNT = number needed to treat; RCT = randomized controlled trial.

Different Durations of Corticosteroid Therapy for COPD Exacerbations

Megan Magovern, MD, and Samuel Sawyer, DO, Forbes Family Medicine Residency Program, Monroeville, Pennsylvania

Author disclosure: No relevant financial affiliations.

**Clinical Question**

Are shorter courses of systemic corticosteroid therapy as safe and effective as conventional, longer courses for
patients with exacerbations of chronic obstructive pulmonary disease (COPD)?

**Evidence-Based Answer**

Treatment of acute exacerbations of COPD with a shorter course of systemic corticosteroids (seven or fewer days) is likely to be as effective and safe as treating with longer courses (more than seven days). There is no significant difference in adverse effects between shorter and longer courses.1 (Strength of Recommendation: B, based on inconsistent or limited-quality patient-oriented evidence.)

**Practice Pointers**

COPD is a chronic, progressive lung condition resulting in airflow limitations. Patients with COPD are at risk of acute exacerbations, which may present as dyspnea, increased cough, and sputum production. Systemic corticosteroids are a mainstay of treatment, but the necessary duration of treatment is debated. The authors of this review assessed whether a shorter course of systemic corticosteroids (seven or fewer days) was as safe and effective as the more conventional 10- to 14-day course.

This Cochrane review included eight studies and 582 patients.1 Five of the studies, which included 519 patients, were hospital based; the remaining three did not specify location. No studies specified whether patients completed the entire treatment course in the hospital. The mean age of participants was 65 to 73 years, and the proportion who were men ranged from 58% to 84%. The studies were conducted in Switzerland, Egypt, Bangladesh, China, Turkey, Thailand, and New Zealand. Only three studies discussed co-interventions, which varied among the studies but included oxygen, inhaled or nebulized bronchodilators, inhaled steroids, theophylline, and, in one study, an histamine H$_2$ antagonist. When co-interventions were specified, they were applied to all participants. Two of the studies treated all patients with antibiotics, although details were not provided. One study used antibiotics only if indicated by certain clinical features. The effect of co-interventions was not included in this review.

Five studies used oral prednisolone, one study used intravenous methylprednisolone, and two studies used a combination of oral and intravenous corticosteroids. Shorter courses of corticosteroids ranged from three to seven days of treatment; longer courses ranged from 10 to 15 days. This review did not discuss whether three days of treatment is equivalent to other courses of up to seven days of treatment. The studies included only patients with severe to very severe COPD, although the criteria for this were not well-defined or consistent among studies. Three studies used pulmonary function testing diagnostic criteria, but even those criteria were not uniform. Primary outcomes included treatment failure, relapse after treatment, and adverse drug effects.

Treatment failure was assessed in four studies (n = 457), as was relapse (n = 478). Adverse effects that were studied included hyperglycemia (n = 345), hypertension (n = 311), and “other” (n = 503), which included gastrointestinal bleeding, symptomatic gastrointestinal reflux, symptoms of congestive heart failure or ischemic heart disease, sleep disturbance, fractures, or depression. There was no difference in any primary outcomes between patients who were treated with systemic corticosteroids for seven or fewer days and those who were treated for more than seven days. The investigators rated the evidence for primary outcomes as moderate, with imprecision as a reported limiting factor.

As noted, the studies did not specifically address outpatient therapy for COPD exacerbations and excluded patients with mild or moderate COPD. Current guidelines from the Global Initiative for Chronic Obstructive Lung Disease recommend treating acute exacerbations of COPD with oral prednisone, 40 mg per day for five days in most patients.2

The practice recommendations in this activity are available at http://www.cochrane.org/CD006897.

**References**
